Previous close | 0.9820 |
Open | 0.9880 |
Bid | 0.9740 x 0 |
Ask | 0.9800 x 0 |
Day's range | 0.9720 - 0.9880 |
52-week range | 0.9600 - 105.0000 |
Volume | |
Avg. volume | 2,363,401 |
Market cap | 1.335B |
Beta (5Y monthly) | 0.22 |
PE ratio (TTM) | 15.68 |
EPS (TTM) | 0.0620 |
Earnings date | 22 Mar 2022 |
Forward dividend & yield | 0.07 (7.16%) |
Ex-dividend date | 05 May 2022 |
1y target est | N/A |
Louvain-La-Neuve, Belgium, December 23, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces a new contract for the installation of a Proteus®ONE1 proton therapy solution with Proton International Arkansas LLC – a joint venture formed by Proton International, the University of Arkansas for Medical Sciences (UAMS), Baptist Health, and Arkansas
Louvain-La-Neuve, Belgium, December 21, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the installation of a Proteus®ONE1 proton therapy solution with the New Mexico Cancer Center in Albuquerque, NM, USA. The contract includes a long-term operation maintenance agreement. The contract is for the delivery of a
IBA – ACQUISITION OF OWN SHARES Immediate Release – December 20th, 2021 Louvain-la-Neuve, Belgium, December 20th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on December 3rd, 2021. Under this program, IBA has requested a financial intermediary to repurchase up to 400.000 IBA ordinary shares on its